Share ownership Sanofi

SAN

FR0000120578

Pharmaceuticals

Market Closed - Euronext Paris Other stock markets 11:55:00 2026-06-15 EDT			After hours 15:59:46
75.54 ^EUR	-1.37%		75.94	+0.52%

11:10am	European Equities Traded in the US as American Depositary Receipts Surge in Monday Trading	MT
06:56am	Global drugmakers invest billions to boost US presence	RE

Share class: Sanofi

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,212,182,886	1,078,879,712 ( 89 %)	11,962,777 ( 0.9869 %)	89 %

Major shareholders: Sanofi

Name	Stocks	%	Valuation
L'ORÉAL 7.303 %	88,670,657	7.303 %	7 791 M €
SANOFI 0.9853 %	11,962,777	0.9853 %	1 051 M €
OFI Invest Asset Management SA 0.2841 %	3,449,102	0.2841 %	303 M €
Goldman Sachs Asset Management International 0.2023 %	2,456,452	0.2023 %	216 M €
Goldman Sachs Asset Management BV 0.2002 %	2,430,707	0.2002 %	214 M €
Sjunde AP-fonden 0.1348 %	1,636,863	0.1348 %	144 M €
State Street Global Advisors Europe Ltd. 0.1253 %	1,520,793	0.1253 %	134 M €
Financière de l'Échiquier SA 0.0861 %	1,045,041	0.0861 %	92 M €
Arkéa Asset Management SA 0.0846 %	1,027,345	0.0846 %	90 M €
Capfi Delen Asset Management NV 0.0822 %	998,419	0.0822 %	88 M €
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Stocks	%	Valuation
Dodge & Cox 1.215 %	29,504,632	1.215 %	1 288 M €
Eaton Vance Management 0.5153 %	12,511,867	0.5153 %	546 M €
Fisher Asset Management LLC 0.4712 %	11,442,163	0.4712 %	500 M €
Merrill Lynch International 0.3906 %	9,484,350	0.3906 %	414 M €
RBC Private Counsel (USA), Inc. 0.289 %	7,016,974	0.289 %	306 M €
Invesco Advisers, Inc. 0.2727 %	6,621,539	0.2727 %	289 M €
Fiduciary Trust Company International 0.2478 %	6,015,938	0.2478 %	263 M €
Barrow, Hanley, Mewhinney & Strauss LLC 0.2425 %	5,887,466	0.2425 %	257 M €
JPMorgan Investment Management, Inc. 0.2307 %	5,600,731	0.2307 %	245 M €
Wells Fargo Bank NA 0.2082 %	5,054,791	0.2082 %	221 M €
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	18.57%
L'Oréal SA	7.3%
Others	1.94%
Sanofi	0.99%
Regal Partners Ltd.	0.21%
SEI Investments Co.	0.05%
Zions Bancorporation NA	0.01%
Northwest Bancshares, Inc. (Pennsylvania)	0.01%
Unknown	70.92%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	14.61%
France	8.98%
United Kingdom	2.02%
Canada	1.03%
Ireland	0.27%
Netherlands	0.25%
Australia	0.23%
Sweden	0.22%
Spain	0.21%
Germany	0.2%
Belgium	0.19%
Switzerland	0.15%
Norway	0.12%
Luxembourg	0.12%
Denmark	0.11%
Italy	0.09%
Finland	0.08%
Austria	0.04%
New Zealand	0.03%
Israel	0.02%
South Africa	0.02%
Japan	0.02%
Hong Kong	0.01%
Mexico	0.01%
China	0.01%
Liechtenstein	0.01%
Cyprus	0.01%
Individuals	-.--%

Based on 1000 largest holdings

Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (81.8%): prescription drugs for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases; - human vaccines (18.2%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas. At the end of 2025, the group had 37 production sites worldwide. Net sales are distributed geographically as follows: France (3.9%), Europe (17.1%), the United States (50.8%), China (6%) and other (22.2%).

Employees

74,846

Sector

Pharmaceuticals

Calendar

Earnings release - Q2 2026

More about the company